Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

SKYE

Skye Bioscience Inc

Last Close
May 03 • 04:00PM ET
13.02
Dollar change
+0.03
Percentage change
0.23 		%
Held by: YOLO HRTS Scroll to Statements
Index- P/E- EPS (ttm)-5.70 Insider Own55.19% Shs Outstand28.06M Perf Week0.15%
Market Cap365.34M Forward P/E- EPS next Y-0.88 Insider Trans0.00% Shs Float12.58M Perf Month17.51%
Income-37.64M PEG- EPS next Q-0.16 Inst Own9.28% Short Float0.37% Perf Quarter225.01%
Sales0.00M P/S- EPS this Y85.38% Inst Trans- Short Ratio1.01 Perf Half Y713.75%
Book/sh-0.17 P/B- EPS next Y-11.46% ROA-357.64% Short Interest0.05M Perf Year300.62%
Cash/sh0.37 P/C35.33 EPS next 5Y- ROE- 52W Range1.44 - 19.41 Perf YTD378.68%
Dividend Est.- P/FCF- EPS past 5Y32.94% ROI- 52W High-32.92% Beta1.68
Dividend TTM- Quick Ratio0.84 Sales past 5Y0.00% Gross Margin- 52W Low804.17% ATR (14)1.40
Dividend Ex-Date- Current Ratio0.84 EPS Y/Y TTM35.07% Oper. Margin0.00% RSI (14)49.08 Volatility3.72% 14.84%
Employees11 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price22.50
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q90.91% Payout- Rel Volume0.75 Prev Close12.99
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume46.42K Price13.02
SMA20-1.81% SMA50-1.01% SMA200123.80% Trades Volume34,863 Change0.23%
Date Action Analyst Rating Change Price Target Change
Apr-12-24Initiated Oppenheimer Outperform $25
Apr-30-24 07:00AM
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
(GlobeNewswire)
Apr-23-24 07:00AM
Skye Bioscience to Present at Upcoming Investment Conferences
(GlobeNewswire) -5.27%
Apr-10-24 08:00AM
Skye Bioscience Uplists to The Nasdaq Global Market
(GlobeNewswire) +39.69%
Mar-11-24 09:20AM
Skye Bioscience Announces $40 Million Private Placement Equity Financing
(Newsfile) -24.95%
Mar-04-24 07:00AM
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
(GlobeNewswire) +7.59%
07:00AM Loading…
Feb-26-24 07:00AM
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
(GlobeNewswire) +13.82%
Feb-07-24 07:00AM
Skye Bioscience to Present at Oppenheimer Investor Conference
(Newsfile) -7.55%
Jan-29-24 08:00AM
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
(Newsfile) +29.03%
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include Nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.